Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2003-02-10
2008-12-16
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S231500, C514S252130, C514S308000, C514S339000, C514S359000, C514S361000, C514S378000, C514S403000, C514S422000, C514S444000, C514S471000, C540S456000
Reexamination Certificate
active
07465718
ABSTRACT:
Ansamycins and methods of preparing and using the same are described. At least some of these ansamycins exhibit one or more of improved aqueous formulation ability, chemical stability, and bioavailability. Some of the derivatives described are dimers. These and others described can include one or more solubilizing groups that have expected merit in rendering the overall compounds useful as drugs and prodrugs.
REFERENCES:
patent: 3595955 (1971-07-01), De Boer et al.
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 4699877 (1987-10-01), Cline et al.
patent: 4918162 (1990-04-01), Slamon et al.
patent: 4968603 (1990-11-01), Slamon et al.
patent: 4975278 (1990-12-01), Senter et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5627165 (1997-05-01), Glazier
patent: 5846749 (1998-12-01), Slamon et al.
patent: 5932566 (1999-08-01), Schnur et al.
patent: 6174875 (2001-01-01), DeFranco et al.
patent: 6210974 (2001-04-01), Gold
patent: 6348209 (2002-02-01), Placke et al.
patent: WO-93-14215 (1993-07-01), None
patent: WO-95-01342 (1995-01-01), None
patent: WO-98-51702 (1998-11-01), None
patent: WO-99-51223 (1999-10-01), None
patent: WO-01-72779 (2001-10-01), None
patent: WO-02-02123 (2002-01-01), None
patent: WO-02-09696 (2002-02-01), None
patent: WO-02-36075 (2002-05-01), None
patent: WO-02-36171 (2002-05-01), None
patent: WO-02-069900 (2002-09-01), None
patent: WO-02-094196 (2002-11-01), None
patent: WO-03-026571 (2003-04-01), None
patent: WO-03-037860 (2003-05-01), None
patent: WO-03-041643 (2003-05-01), None
patent: WO-03-050295 (2003-06-01), None
patent: WO-03-066005 (2003-08-01), None
patent: WO-03-072794 (2003-09-01), None
Ausubel et al.,Current Protocols in Molecular Biology, John Wiley & Sons, NY 1994.
Bagatell, R. et al., “Induction of a Heat Shock Factor 1-dependent Stress Response Alters the Cytotoxic Activity of Hsp-90-binding Agents,” Clinical Cancer Res., Aug. 2000, vol. 6, pp. 3312-3318.
Berge et al., “Pharmaceutical Salts,” J. Pharm. Sci. 66:1-19 (1977).
Boehm et al., J. Org. Chem. 51:5447-5450 (1986).
Buchner, Trends Biochem, Sci. 24:136-141 (1999).
Buchwald et al., Surgery 88:507 (1980).
Cailleau, R. et al., “Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization,” In Vitro 14:911-915, 1978, PubMed 730202.
Caplan, Trends Cell. Biol. 9:262-258 (1999).
Chiosis, G. et al., “A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells,” Chem. & Biol. 8 (2001) 289-299.
Corey et al., J. Am Chem. Soc., 96: 5581-5583 (1974).
Chumpradit, S. et al., “Fluorinated and iodinated dopamine agents: D2 imaging agents for Pet and Spect,” J. of Med. Chem. 36 (2):221-8 (1993).
Dai, K. et al., J. Biol. Chem. 271:22030-4 (1996).
De La Torre-Bueno, J. et al., Modern Pathology 13:221A (2000).
Erlichman et al., Proc. AACR (2001) 42, Abstract 4474.
Eng et al., Bull. Chim. Soc. Belges 95:895-914 (1986).
Federal Register 66 (129): 35443-35444.
Goodman and Gilman,The Pharmacological Basis of Therapeutics, current ed., Pergamon Press.
Goodson,Medical Applications of Controlled Release, vol. 2, pp. 115-138 (1984).
Grenert, J.P. et al., J. Biol. Chem. 272:23843-50 (1997).
Hanson et al., Int. J. Appli. Radiat. Isot. 35:810-812 (1984).
Harlow et al.,Antibodies: A Laboratory Manual, 2nded., Cold Spring Harbor Laboratory Press, Cold Spring Harbor,NY 1988.
Hartmann, F. et al., Int. J. Cancer 70:221-9 (1997).
Howard, G., “Labeling Proteins with Fluorochromes,”Methods in Nonradioactive Detection, T. Hward, Ed. Appleton and Lange, Norwalk Conn USA 1993, pp. 39-68.
Jalilian et al., J. Pharm. Pharmaceut. Sci. 3:114-124 (2000).
Kelland, L.R. et al., “DT-Diaphorase Expression and Tumor Cell Sensitivity to 17-Allylamino, 17-Demethoxygeldanamycin, An Inhibitor of Heat Shock Protein,” J. Natl. Cancer Inst., Nov. 17, 1999, vol. 91, No. 22, pp. 1940-1949.
Kurokawa, H. et al., Cancer Res. 60:5887-5894 (2000).
Langer, Science 249:1527-1533 (1990).
Mandelkern et al., “Positron emission tomography in cancer research and treatment,” Technologies in Cancer Research and Treatment 1(6):423-39 (2002).
Marcu, M.G. et al., “The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-Binding Domain in the Carboxyl Terminus of the Chaperone,” J. Biol. Chem., Nov. 24, 2000, vol. 274, No. 47, pp. 37181-37186.
Miller, P. et al., Cancer Research 54:2724-2730 (1994).
Mimnaugh, E.G. et al., J. Biol. Chem. 271:22796-801 (1996).
Mitchell, M.S. and Press, M.F., Semin. Oncol. Suppl.12:108-116 (1999).
Muise-Heimericks et al., J. Biol. Chem. 273:29864-72 (1998).
Panaretou et al., Embo J. 17:4829-4836 (1998).
Press, M. et al., Modern Pathology 13:225A (2000).
Prestwich et al., Tetrahedron 40:529-537 (1984).
Prodromou, C. et al., Cell 90:65-75 (1997).
Qualls, et al., “Synergistic Photoxicity of Chloroaluminum Phthalocyanine Tetrasulfonate Delivered via Acid-Labile Diplanmenylcholine-Folate Lipsomes,” Int. J. of Cancer 93:384-392 (2001).
Remington,Pharmaceutical Sciences, current ed., Mack Publishing Co., Easton PA USA.
Sambrook et al.,Molecular Cloning: A Laboratory Manual, 2nded., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989.
Saudek et al., N. Eng. J. Med. 321:574 (1989).
Scheibel et al., PNAS USA 96A:1297-1302 (1999).
Schneider et al.,, PNAS USA 93:14536-41 (1996).
Schulte et al., Biochem. Biophys. Res. Commun. 239-655-9 (1997).
Schulte et al., J. Biol. Chem. 270:24585-8 (1995).
Sefton, CRC Grit. Ref. Biomed. Eng. 14:201 (1987).
Segnitz, B. and Gehring, U., J. Biol. Chem. 272:18694-18701 (1997).
Sepp-Lorenzino et al., J. Biol. Chem. 270:16580-16587 (1995).
Smith, D.F. et al., Mol. Cell. Biol. 15:6804-12 (1995).
Stebbins et al., Cell 89:239-250 (1997).
Stepanova et al., Genes Dev. 10:1491-1502 (1997).
Treat et al.,Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Bernstein and Fidler (eds.), Liss, NY USA pp. 353-365.
Vasilevskaya et al., Cancer Res. 59:3935-40 (1999).
Voges, Rolf and Pleiss, Ulrich, eds.,Synthesis and Applications of Isotopically Labelled Compounds, vol. 7. , John Wiley & Sons, Ltd. (2001).
Whitesell et al., PNAS USA 91:8324-8328 (1994).
Zimny et al., “Positron emission tomography scanning in gynecologic and breast cancer,” Curr. Op. in Obstetrics and Gynecology 15(1):69-75 (2003).
Ojwang et al., Antimicrobial Agents and Chemotherapy 39:2426-2435 (1995).
Buckheit et al, AIDS Research and Human Retroviruses 7:295-302 (1991).
Rinehart, Jr., K.L. and Shield, L.S., “Chemistry of the Ansamycin Antibiotics,”Progress in the Chemistry of Organic Natural Products, pp. 231-307.
Melton, R.G. and Sherwood, R.E., J. National Cancer Inst. 88:153-165 (1996).
Neel et al., Bioorg. Med. Chem. Lett. 8:47-50 (1998).
Boehm Marcus F.
Burrows Francis J.
Fan Junhua
Fritz Lawrence C.
Le Brazidec Jean-Yves
Conforma Therapeutics Corporation
Finnegan Henderson Farabow Garrett & Dunner LLP
Kifle Bruck
LandOfFree
Ansamycins having improved pharmacological and biological... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ansamycins having improved pharmacological and biological..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ansamycins having improved pharmacological and biological... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043677